Prognostic Impact of MYCN Amplification, 1p Deletion and 11q Deletion in Neuroblastoma Patients

Abstract

Neuroblastoma is characterized by wide clinical heterogeneity from tumors prone to spontaneous regression to highly aggressive disease that requires multimodal chemotherapy with autologous stem cells transplantation. Patient’s age and stage of the disease were described as prognostic factors. Different genetic aberrations were analyzed as potential predictive signs of poor outcome. MYCN gene amplification, 1p and 11q deletions are associated with aggressive tumor behavior, advanced stage of the disease and unfavorable outcome. In current report we analyzed molecular mechanisms and prognostic significance of indicated genetics abnormalities.